Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login



PHE supports use of trivalent flu vaccine in older people to reduce hospitalisations

New Public Health England (PHE) guidance supports the use of the adjuvanted trivalent influenza vaccine (aTIV) in older people saying that it would lead to large reductions in GP consultations and hospitalisations.

The guidance, which is based on an analysis of existing evidence, says that although the quadrivalent vaccine offers the potential to provide broader direct protection against the two major influenza B strains, the inclusion of the live attenuated quadrivalent vaccine in the childhood vaccination programme provides indirect protection to older people by reducing transmission.

The benefits of the quadrivalent vaccine for older people are limited and should instead be considered for adult at-risk groups, such as pregnant women, PHE says.

Priority for the aTIV should be for those aged 75 years and above, but the vaccine would also be effective and cost-effective in those aged 65–74 years. The guidance states: “Trivalent adjuvanted vaccine is a more appropriate choice than standard quadrivalent vaccine for older people.”

However, on 30 January 2018, GlobalData, a leading data and analytics company, said that the NHS and other European healthcare providers should consider expanding administering of quadrivalent vaccines in order to protect against “Aussie flu”, which is thought to now be the most prevalent strain in Europe. GlobalData said it believed that the extra cost of the vaccine amounted to a better long-term investment than the trivalent vaccine.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2018.20204328

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Clinical Pharmacokinetics

    Clinical Pharmacokinetics

    A practical guide to the use of pharmacokinetic principles in clinical practice. Includes case studies with questions and answers.

    £33.00Buy now
  • Strategic Medicines Management

    Strategic Medicines Management

    A practical guide to influencing the availability of medicines, and policies of their use. Focuses on the strategic elements of medicines management.

    £33.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • older person receiving flu jab from GP

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.